Nucleic acid constructs

Details Nucleic acid constructs Nucleic acid constructs

2005-04-19

2005-04-19

Li, Q. Janice (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C435S320100, C424S093210

Reexamination Certificate

active

06881723

ABSTRACT:
Recombinant nucleic acid molecules are described. The molecules have a first sequence encoding a Hepatitis B virus core antigen and a second sequence encoding at least one T cell epitope inserted within the first sequence. Vectors and compositions containing these molecules are also described. Methods of eliciting an immune response using these molecules are also described.

REFERENCES:
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4629782 (1986-12-01), Chan et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 4981782 (1991-01-01), Judd et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5091188 (1992-02-01), Haynes
patent: 5100792 (1992-03-01), Sanford et al.
patent: 5120657 (1992-06-01), McCabe et al.
patent: 5149655 (1992-09-01), McCabe
patent: 5179022 (1993-01-01), Sanford et al.
patent: 5204253 (1993-04-01), Sanford
patent: 5371015 (1994-12-01), Sanford et al.
patent: 5478744 (1995-12-01), Sanford et al.
patent: 5584807 (1996-12-01), McCabe
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5630796 (1997-05-01), Bellhouse et al.
patent: 5658892 (1997-08-01), Flotte et al.
patent: 5738852 (1998-04-01), Robinson et al.
patent: 5865796 (1999-02-01), McCabe
patent: 5899880 (1999-05-01), Bellhouse et al.
patent: 6004286 (1999-12-01), Bellhouse et al.
patent: 6010478 (2000-01-01), Bellhouse et al.
patent: 6013050 (2000-01-01), Bellhouse et al.
patent: 6194389 (2001-02-01), Johnston et al.
patent: 20020018766 (2002-02-01), Roberts et al.
patent: 1319628 (1988-08-01), None
patent: 0155146 (1985-09-01), None
patent: 0390435 (1990-10-01), None
patent: WO 8905349 (1989-06-01), None
patent: WO 9001949 (1990-03-01), None
patent: WO 9100359 (1991-01-01), None
patent: WO 9107487 (1991-05-01), None
patent: WO 9319183 (1993-09-01), None
patent: WO 9409819 (1994-05-01), None
patent: WO 9421797 (1994-09-01), None
patent: WO 9424263 (1994-10-01), None
patent: WO 9519799 (1995-07-01), None
patent: WO 9520660 (1995-08-01), None
patent: WO 9604947 (1996-02-01), None
patent: WO 9612513 (1996-05-01), None
patent: WO 9614855 (1996-05-01), None
patent: WO 9620022 (1996-07-01), None
patent: WO 9732987 (1997-09-01), None
patent: WO 9740163 (1997-10-01), None
patent: WO 9748485 (1997-12-01), None
patent: WO 9810750 (1998-03-01), None
patent: WO 9846263 (1998-10-01), None
Londono et al, Vaccine 1996;14:545-52.*
Tindle et al, Virol 1994;200:547-57.*
Fuller et al, Vaccinces 96, Eds: Brown, Fred. Cold Spring Harbor Lab Press, Sep. 1995;87-91.*
Maryanski et al, Hum Immunol 1997;54:117-28.*
RA Strugnell et al., Immunology and Cell Biology, “DNA vaccines for bacterial infections,” 1997, 75:364-369.*
Schodel F.et al. hybrid heaptitis B virus core antigen as a vaccine carrier moiety:I Presentation of foreign epitope. 1996, Jouranl of Bioteology, vol. 44 pp. 91-96.*
Milich D. et al. The hepatitis nucleocapsid as a vaccien carreir moiety. 1995, Ann. N.Y.Acad. Sci. vol. 754, pp. 187-201.*
Loktev V. et al. Design of immunogen as component of a new generatin of molecular vaccines. 1996, Jouranl of Bioteology, vol. 44 pp. 129-137.*
Leitner W. et al. DNA and RNA based vaccines: principles, progress and prospects. 2000, Vaccine, vol. 18, pp. 765-777.*
Bachmann m. et al, In vivo versus In vitor assays for assessment of T and B cell function. 1994, Current opinion in immunology, vol. 6, pp. 320-326.*
Orkin S. et al. Report and recommendatios of the panel to assess the NIH investment in research on gene therpay. 1995.*
Retorviruses, Ed. Coffin Cold Spring Harbor Press, 1997.*
Yasutomi et al. , A vaccine-elicited , single viral epitope-specific cytotoxic T lyphocyte response not protect against intravenous cell-free simsian immunodeficiency virus challenge. 1995, journal of virology, vol. 69,pp. 2279-2284.*
Schodel F. et al. The position of heterologous epitopes inserted in hepatitis B virus core particles. 1992, Journal of Virology, vol. 66, pp. 129-137.*
Schodel F. et al. inmmunity to malaria elicited by hybrid hepatitis B virus core particle carrying circumsporozoit protein epitopes. 1994, The journal of experimental medicine, vol. 180, pp. 1037-1046.*
Ciernik F. et al. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. 1996, Journal of immunology, vol. 156, pp. 2369-2375.*
A. Aggarwal et al., “OralSalmonella:Malaria Circumsporozoite Recombinants Induce Specific CD8+ Cytotoxic T Cells,” The Journal of Experimental Medicine, vol. 172, pp. 1083-1090 (1990).
M. Del Val et al., “Protection Against Lethal Cytomegalovirus Infection by a Recombinant Vaccine Containing a Single Nonameric T-Cell Epitope,” Journal of Virology, vol. 65, pp. 3641-3646 (1991).
D. Doolan et al., “Circumventing Genetic Restriction of Protection Against Malaria with Multigene DNA Immunization . . . ,” The Journal of Experimental Medicine, vol. 183, pp. 1739-1746 (1996).
A. Malik, “Induction of Cytotoxic T Lymphocytes Against thePlasmodium falciparumCircumsporozoite Protein . . . ,” Infection and Immunity, vol. 61, pp. 5062-5066 (1993).
W. Weiss et al., “Cytotoxic T Cells Recognize a Peptide from the Circumsporozoite Protein on Malaria-Infected Hepatocytes,” The Journal of Experimental Medicine, vol. 171, pp. 763-773 (1990).
Haynes et al. (1991)Mol. Immunology 28:231-234.
Rhim et al. (1991)J. Virology 65:4555-4564.
Rousseaux-Prevost et al. (1991)Molecular Immunology 28:943-949.
Ferrari et al. (1991)J. Clin. Invest. 88:214-222.
Haynes et al. (1994)Aids Res. and Human Retroviruses 10(suppl..2):S43-S45.
Sedegah et al. (1994)Proc. Natl. Acad. Sci. USA 91:9866-9870.
Fuller et al. (1995)Annals NY Acad Sci 772:282-284.
Fynan et al. (1995)Int. J. Immunopharmac. 17:79-83.
Schodel et al. (1996)Intervirology 39:104-110.
Kuhrober et al.(1997)Int. Immunol. 9:1203-1212.
Schodel et al. (1992)J. Virology 66:106-114.
Remington's Pharmaceutical Sciences (1980) Mark Publishing Company, Pennsylvania, pp1483-1484 and 1535.
Townsend et al. (1984)Cell 39:13.
Townsend et al. (1985)Prog. Allergy 36:10.
Sanford et al. (1987) “Delivery of substances into cells and tissues using a particle bombardment process,”Particulate Science and Technology 5:27-37.
Klein et al (1987) “High velocity microprojectiles for delivering nucleic acids into living cells,”Nature 327:7-73.
Tang et al. (1988)J. Virology 62:4745-4751.
Zelenin et al. (1989) “Genetic transformation of mouse cultured cells with the help of high-velocity mechanical DNA injection,”FEBS Letters 244:65-67.
Milich (1989)Advances in Immunology 45:195.
Schodel et al. (1989)Infection and Immunity 57:1347-1350.
Stahl et al. (1989)Proc. Natl. Acad. Sci. USA 86:6283-6287.
S.A. Johnston (1990) “Biolistic transformation: microbes to mice,”Nature 346:776-777.
Poznansky et al. (1991)J. Virology 65:532-536.

Affiliated with

Also associated with

Rating

Nucleic acid constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acid constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid constructs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3421192